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Abstract
Background: Melanoma is the major cause of skin cancer deaths and melanoma incidence doubles every 10 to 20 years.
However, little is known about melanoma pathway aberrations. Here we applied the robust Gene Identification Signature
Paired End diTag (GIS-PET) approach to investigate the melanoma transcriptome and characterize the global pathway
aberrations.
Methods: GIS-PET technology directly links 5' mRNA signatures with their corresponding 3' signatures to generate, and
then concatenate, PETs for efficient sequencing. We annotated PETs to pathways of KEGG database and compared the
murine B16F1 melanoma transcriptome with three non-melanoma murine transcriptomes (Melan-a2 melanocytes, E14
embryonic stem cells, and E17.5 embryo). Gene expression levels as represented by PET counts were compared across
melanoma and melanocyte libraries to identify the most significantly altered pathways and investigate the expression
levels of crucial cancer genes.
Results: Melanin biosynthesis genes were solely expressed in the cells of melanocytic origin, indicating the feasibility of
using the PET approach for transcriptome comparison. The most significantly altered pathways were metabolic pathways,
including upregulated pathways: purine metabolism, aminophosphonate metabolism, tyrosine metabolism, selenoamino
acid metabolism, galactose utilization, nitrobenzene degradation, and bisphenol A degradation; and downregulated
pathways: oxidative phosphorylation, ATPase synthesis, TCA cycle, pyruvate metabolism, and glutathione metabolism.
The downregulated pathways concurrently indicated a slowdown of mitochondrial activities. Mitochondrial permeability
was also significantly altered, as indicated by transcriptional activation of ATP/ADP, citrate/malate, Mg++, fatty acid and
amino acid transporters, and transcriptional repression of zinc and metal ion transporters. Upregulation of cell cycle
progression, MAPK, and PI3K/Akt pathways were more limited to certain region(s) of the pathway. Expression levels of
c-Myc and Trp53 were also higher in melanoma. Moreover, transcriptional variants resulted from alternative transcription
start sites or alternative polyadenylation sites were found in Ras and genes encoding adhesion or cytoskeleton proteins
such as integrin, β-catenin, α-catenin, and actin.
Conclusion: The highly correlated results unmistakably point to a systematic downregulation of mitochondrial activities,
which we hypothesize aims to downgrade the mitochondria-mediated apoptosis and the dependency of cancer cells on
angiogenesis. Our results also demonstrate the advantage of using the PET approach in conjunction with KEGG database
for systematic pathway analysis.
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Background
Cancers are caused by multiple genetic and/or epigenetic
alterations [1-4]. These alterations include activation of
oncogenes, inactivation of tumor suppressor genes, muta-
tions that cause chromosome instability [5], and muta-
tions that affect key pathways such as apoptosis, MAPK,
cell cycle progression, Wnt/β-catenin, metastasis, and ang-
iogenesis [6-9].
Melanomas are among the most common cancers in
human and their incidences continue to rise at a pace
faster than any other malignancy [10]. Genetic alterations
in melanoma signaling pathways have been reported
recently [3,11]; however, global pathway aberrations
remain unclear. We applied the robust Gene Identifica-
tion Signature Paired-End diTag technology (GIS-PET) to
reveal the global pathway aberrations in melanoma by
using the murine melanoma cell line B16F1 as a model
system. B16F1 is a metastatic clone generated from the
spontaneous melanoma cell line B16F0. Some in vitro and
in vivo studies of this cell line, including deletion in Ink4a/
Arf exons and p53 protein expression level, have been well
documented and can serve as controls for data validation
[12,13].
Previous transcriptome studies were mostly performed
with high throughput microarray or Serial Analysis of
Gene Expression (SAGE) approaches. Microarray is a well
commercialized technology [14]. It uses mRNAs from a
given cell line or tissue to generate a labeled target sample,
which is hybridized to a large number of DNA sequences,
each representing a gene. The signal intensity of each
hybridized DNA sequence is subtracted by a control and
analyzed with software packages not only for data
processing, but also for mapping gene-expression clusters
to integrated pathways [15]. SAGE is another powerful
method for studying transcriptome profiles. It extracts
short, positionally defined, tag signatures from expressed
mRNAs and subsequently correlates the signatures to
genomic coordinates using the UniGene virtual database
[16,17]. The SAGE method is also supported by a number
of software and public databases which have been made
available for cancer studies [18,19]. Both of these
approaches have been applied to melanoma studies. The
focuses of these studies, however, were mainly on genes,
gene sets, or pathway annotations. To our best knowledge,
application of these technologies (or any other technolo-
gies) to the global study of melanoma pathway aberra-
tions is presently not available.
GIS-PET was originally developed to facilitate the study of
transcriptome profiles. It covalently links the correspond-
ing 5' and 3' signatures of full-length transcripts into PET
sequences of around 36 bp (18 bp from each of the 5' and
3' signatures of the same mRNA transcript) and concate-
nates multiple PETs to form longer stretches of cDNA frag-
ments for high throughput sequencing [20,21]. We have
shown that GIS-PET is able to precisely locate the tran-
scription start sites (TSSs) and the polyadenylation sites
(PASs) of expressed genes. When combined with chroma-
tin immunoprecipitation (ChIP) approach, PET method
is able to precisely map the genome-wide transcription
factor binding sites (TFBSs), as demonstrated in the stud-
ies of human tumor suppressor p53 [22] and murine
developmental regulators OCT4 and NANOG [23].
For this investigation, we generated PET transcriptomes
from 4 independent but related murine cell types: B16F1
melanoma cells, Melan-a2 melanocytes, E17.5 embryo,
and E14 embryonic stem cells. PETs were mapped against
University of California at Santa Cruz (UCSC) genome
database mm5 and annotated to known genes. The asso-
ciated genes were subsequently annotated to various path-
ways using KEGG murine database. We adopted
hypergeometric distribution to assess pathway alterations
based on a few reasons. First, hypergeometric distribution
is one of the most commonly used analytical methods for
microarray transcriptome analysis. Although there are dif-
ferences between PET and microarray technologies, their
analytical tools are mutually applicable to a great extent.
Secondly, our transcriptome libraries contain large data-
sets, and variations resulted from the differences in analyt-
ical metrics become insignificant for large datasets.
Moreover, our libraries do not contain replicates or serial
samples collected from different time points and are thus
suitable for analysis with the hypergeometric approach.
Because melanocytic cells (including B16F1 and Melan-
a2) have the unique capability to produce melanin, while
embryonic cells (including E14 stem cells and E17.5
embryo) do not, we first compared the PET counts of mel-
anin biosynthesis genes between melanocytic cells and
embryonic cells to ensure the feasibility of using PET
count to represent the expression level. Melanogenesis in
mice is a complex process involving more than 150 genes
located in about 50 loci, which exert functions in various
processes including melanin biosynthesis, aggregation
and transportation [24] We focused on melanin biosyn-
thesis because this process has been well characterized.
The results strongly support the idea of using a PET
approach for pathway comparisons.
We subsequently evaluate the degree of pathway perturba-
tion library-wide using the hypergeometric approach so as
to identify the most significantly altered pathways in
melanoma cells. We also looked into the pathways previ-
ously shown to be implicated in tumorigenesis and iden-
tified the transcriptional variants resulted from alternative
TSSs or alternative PASs, which may play important roles
in melanoma tumorigenesis and pathway aberrations.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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Our data revealed a systematic redistribution of workload
for multiple metabolic pathways leading to an enhanced
detoxification capability and a reduction of electron trans-
port chain (ETC) usage through a global downregulation
of mitochondria-harbored pathways. In parallel, the
revamping was accompanied by shattered tumor suppres-
sor pathways and apoptotic pathways, and redefined
mitochondrial permeability. Thus, functional perturba-
tions in multiple molecules, caused by multiple genetic
and/or epigenetic alterations, affect multiple metabolic
and signal transduction pathways and the combinatorial
effect ultimately determines cancer cell survival. Our dis-
coveries should be able to facilitate drug target discoveries
for cancer therapy.
Methods
Cell cultures
As described previously [25], B16F1 murine melanoma
cells were grown in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS, Gibco-BRL), plus penicillin (100 u/ml), and strepto-
mycin (100 μg/ml, Invitrogen). Cells were cultured at
37°C with 5% CO2. Melan-a2 murine melanocytes were
grown in RPMI 1640 medium supplemented with 10%
FBS (Gibco-BRL), plus penicillin (100 u/ml), streptomy-
cin (100 μg/ml), 12-0-tetradecanoyl phorbol acetate (200
nM, Sigma), and cholera toxin (200 pM, Sigma). Cells
were cultured at 37°C with 10% CO2. Embryonic day 14
(E14) mouse ES cells were either co-cultured with mouse
primary embryonic fibroblast feeders or cultured under
feeder-free conditions [23]. Cells were maintained in
DMEM (GIBCO), supplemented with 15% heat-inacti-
vated fetal bovine serum (GIBCO), plus β-mercaptoetha-
nol (0.055 mM, GIBCO), L-glutamine (2 mM), MEM (0.1
mM nonessential amino acid), penicillin/streptomycin
(5,000 units/ml) and leukemia inhibitory factor (1,000
units/ml, Chemicon).
Library construction and PET extraction
Methods for constructing GIS-PET transcriptome libraries
and scripts for PET extraction are available for download
[26], and can also be found from our previous publica-
tions [20,27]. Spacers, which interpose PETs in the raw
sequences, are defined by the vectors and restriction
enzymes used for library constructions. The 5' most spacer
is denoted as 5' spacer; the 3' most spacer as 3' spacer; the
major internal spacer as spacer1; and the minor internal
spacer, which might be generated from incomplete enzy-
matic manipulation, as spacer2. Libraries SMT001 (B16F1
melanoma library), SMN001 (Melan-a2 melanocyte
library) and SME006 (E17.5 embryo library) had the
same 5' spacer (GATCGAC), spacer1 (GTCGGATCCGAC),
spacer2 (GTCGCGAC), and 3' spacer (GTCGATC), while
library MoEScom (E14 embryonic stem cell library) had
all spacers of the same sequence 'GTCGGATCCGAC'. The
minimum and maximum ditag lengths were 34 and 40,
respectively. PET-Tool first identified the spacers and
extracted the PET candidates interspersed between the
spacers. PET candidates containing more than 8 bp of con-
secutive A, T, G, or C in either the 5' or 3' tag region were
removed, due to the facts that these PET sequences were
very likely to be artifacts or contaminants introduced in
the wet-lab. N-containing PETs were also removed. The
PET extraction process generated a pool of unique PETs
(each with a unique sequence) for each library, and each
unique PET might have a single or multiple copy
number(s), termed PET count. Prior to library compari-
son, PET counts were normalized to counts per million
(cpm) based on the total PET counts of the original librar-
ies, i.e. Every PET count was scaled up by the factor
1,000,000/(total PET count) before the comparison.
PET-to-genome mapping
Compressed Suffix Arrays (CSA) constructed from the
UCSC mouse genome assembly mm5 were used for map-
ping. Each PET was split into a 5' tag and a 3' tag. From the
5' tag, a set of 9 subsequences were generated by allowing
the tag subsequence to start from position 1, 2, or 3, and
end at position 17, 18, or 19. The remaining portions
formed the 3' subsequences. These subsequences were
subjected to mapping against the CSA chromosome con-
structs. The mapping process identified the chromosome
location(s), if present, for each subsequence. Mismatches,
deletions, and insertions were not allowed during map-
ping and the minimum perfect match lengths for the 5'
and 3' subsequences were set to 16 and 14 bp, respec-
tively. The 5' hits were then paired with the 3' hits to iden-
tify the genomic target locations of the PETs. The criteria
for pairing were: both the 5' and 3' mapping locations had
to be on the same chromosome, same strand, in 5' fol-
lowed by 3' order, and within 1 million bp in distance.
PETs were then split into PET1 - PET>10 categories based
on the number of genomic targets. PETs that could not be
mapped under these parameters were assigned to the
PET0 category; PETs that mapped to single locations were
assigned to the PET1 category; and so on. This study used
only PET1 ditags to avoid complication. PET sequence
data will be available to the public through T2G website
[28] when the paper is published.
Individual PET-to-exon designation
To assign PET tags to exons, we compared the 5' and 3'
mapping locations of each PET to the known gene exons
downloaded from the knownGene, refSeq, and MGC
tables of the UCSC annotation database (herein, a known
gene refers to a gene that matches any of these sources).
The PET-to-exon designation is the basis for the "PET-to-
transcription unit" annotation. For a PET generated from
an mRNA transcribed from a known gene, the 5' tag is
expected to map to the first exon and the 3' tag to the lastBMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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exon of the same gene. However, there were situations
where a PET mapped to a novel exon of a known gene or
it might map to a known exon but with an offset. To
absorb variations in exon boundaries, we extended the
starting and ending positions of each exon outwards by
100 bp (Figure 1). A tag, either the 5' or the 3' tag, with a
mapping location within such defined exon boundaries
was considered a successful match; otherwise, if either end
of a PET mapped to the intronic region, it was considered
as an intragenic tag. For the terminal exons, we extended
the range by 1 Kb, to include plausible novel TSSs or PASs.
If only one side, either the 5' or the 3' tag, matched an
exon of a known gene, more stringent criteria were
applied to avoid faulty exon annotation. The criteria were:
the span between the 5' and 3' tags had to be less than
300,000 bp, and the minimum perfect match lengths for
the 5' tag and the 3' tag had to be at least 17 bp and 15 bp,
respectively, instead of 16 bp and 14 bp used in default
mapping.
We also used a 'SET' system to represent the qualities and
natures of PETs that mapped to a particular "transcription
unit" ('S', 'E' and 'T' stands for the starting exon, ending
exon, and total number of exons, respectively). As an
example of a perfect PET-to-transcription unit annotation,
'S1E5T5' indicates that the 5' tag matches to exon1, and
the 3' tag matches to exon5 of the same transcription unit
that has a total of 5 exons. As an example of an imperfect
PET-to-transcription unit annotation, S1E3-4T5 indicates
that the 5' tag matches to exon1, and the 3' tag matches to
the third intron of the same transcription unit that has a
total of 5 exons. The geneID of the transcription unit that
owned the PET-associated exon(s) was annotated to the
PET with the expression level shown as the PET count. For
UCSC database, each geneID has a corresponding gene-
Symbol (terminology as in UCSC annotation database)
and multiple geneIDs may point to the same geneSymbol
(N:1 relation).
PET clustering and cluster-to-gene annotation
Here a GIS-PET cluster is defined as a genomic origin, or a
gene, that expresses a group of related transcription units.
In practice, PET clustering was conducted for two catego-
ries separately: one for known gene annotated PETs (gene-
based) and the other for un-annotated PETs (coordinate-
based, or chromosome location-based). The gene-based
clustering was conducted by the following steps: First, all
PETs were separated based on the 'SET' designation. PETs
with the same starting and ending exons were grouped
into the same "sub-cluster" representing a distinguishable
"transcription unit", and their counts were summed to
represent the expression level of that transcription unit.
Second, all the transcripts belonging to the same gene-
Symbol were further grouped into the same "cluster" with
PET counts summed to represent the overall expression
level of the gene. Lastly, for a cluster containing multiple
geneSymbols, the geneSymbol associated with the major-
ity of PETs was annotated to that cluster and all PET
counts were summed to represent the expression level of
PET-to-gene annotation Figure 1
PET-to-gene annotation. PET-to-gene annotation is based on tag-to-exon annotation, through which the mapping locations 
of the 5' and 3' tags of each PET1 ditags (PETs with unique targets) are compared with exon locations of the knownGene, ref-
Seq and MGC genes of UCSC mm5 database. To absorb the variations that may be present, exon boundaries are extended 100 
bp (for internal boundaries) or 1 Kb (for external boundaries). Under such definition, both 'a' and 'b' (5' tags) match to exon 1, 
and both transcripts are denoted as S1E3T3; 'c' (5' tag) matches to intron 1, and the transcript is denoted as S1-2E3T3; while 
'd' (3' tag) matches to exon 3, and the transcript is denoted as S2E3T3. All these PETs are annotated to the same gene. S, start-
ing exon; E, ending exon; T, total exon.
Exon 1 Exon 2 Exon 3
1 Kb 1 Kb 100bp 100bp 100bp 100bp
a
b
c
d
Exon 1 Exon 2 Exon 3
1 Kb 1 Kb 100bp 100bp 100bp 100bp
a
b
c
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that gene cluster. Since only known gene PETs can be cor-
related to the KEGG pathways, there will be no further dis-
cussion of PETs clustered by the coordinate-based
clustering approach.
Gene level melanoma-melanocyte comparison
B16F1 melanoma and Melan-a2 melanocyte transcrip-
tomes were compared using known genes present in
either or both libraries (Figure 2). Results were partitioned
into 3 mutually exclusive sets: genes that are exclusive to
the B16F1 melanoma library, genes that are shared by
both libraries, and genes that are exclusive to the Melan-
a2 library. Genes highly expressed in melanoma, but not
in melanocytes (or with low expression levels) were listed.
Pathway level melanoma-melanocyte comparison
To facilitate data analysis, we built a local mirror site of
KEGG pathway, containing a total of 141 pathways, with
a slight modification to reflect our local data status (Figure
3). PET associated genes were correlated to their corre-
sponding KEGG IDs using the file 'keggPathway.txt' avail-
able at UCSC database. If the knownGene ID for a PET
cluster was not available (e.g. the PETs mapped to a ref-
Gene entity) we either converted refGene ID to known-
Gene ID using 'kgXref.txt' or used the gene symbol to map
it to the corresponding KEGG ID. We modified the origi-
nal pathway images by adding solid squares, each repre-
senting a library, to the upper left corner of the gene box
to indicate the status of isoform coverage by the libraries.
The solid squares were highlighted red, yellow, or blue to
indicate that the isoforms all matched, partially matched,
or did not match at all, respectively. Links were also cre-
ated on the solid boxes to allow easy access to additional
information. Multiple PET libraries could be displayed in
the same page to facilitate side-by-side comparison.
Another feature added to the local KEGG pathway data-
base was the expression graph for making cross library
comparison over PET counts of all gene isoforms of a par-
ticular pathway to enhance visualization (Figure 4).
Testing the feasibility of using PET count to measure gene 
expression level
The melanin biosynthesis pathway was not listed in the
KEGG database, and the analysis was conducted alterna-
tively with the following steps: First, we used UCSC
mouse genome database mm5 and the Gene Ontology
database [29] to identify all the melanin biosynthesis
related genes. Second, PETs mapped to these genes were
identified from all four libraries and their counts were
added up for each gene and each library. Then, the PET
counts of each gene were compared across all four librar-
ies.
Identification of most significantly altered pathways with 
hypergeometric distribution
Global pathway comparison was conducted by compar-
ing all pathways using a hypergeometric distribution
method with a minor modification to identify the path-
ways with most significant aberrations. This was con-
ducted by the following steps: Given a gene, its expression
ratio r was defined as:
where s0 is a small positive value representing the pseudo-
count for stabilizing the ratio when the expression level of
the gene is low [30]. The s0 was empirically determined to
be 5 in our study. With the criterion of 1.5-fold change as
the cutoff, we identified upregulated genes (r ≥ 1.5), and
downregulated genes (r ≤ 0.67). For each KEGG pathway,
we calculated the hypergeometric p-value which indicates
the enrichment of regulated genes in the pathway. Path-
ways with p-values of 0.005 or less were considered to be
significantly altered. Manual curation was applied to
ensure the quality of pathway analysis.
TSS/PAS variants
We used the 'SET' transcription unit definition described
above to differentiate transcriptional variants resulted
from alternative TSSs or alternative PASs Transcription
units sharing the same values of 'S', 'E' and 'T' were con-
sidered as common ones. Otherwise they were considered
as library specific. The results were split into seven catego-
ries.
Partial pathway analysis and manual curation
In general, KEGG pathways are loosely defined and some
are partially overlapped with each other; thus, whole
pathway comparison can be overgeneralized and over-
looks local transcriptional architectures. To compensate
this potential problem, some pathways were partially ana-
lyzed or manually curated (see Results and Discussion).
For example, the galactose-glucose interconversion path-
way was extracted from the galactose metabolism path-
way to focus on genes directly involved in the galactose
and glucose interconversion process. Similarly, the RAS-
ERK sub-pathway was extracted from the MAPK pathway
and the expression of cyclins and CDKs was obtained
from the cell cycle pathway. Manual curation was con-
ducted for the most significantly altered pathways to
ensure accuracy.
Results and discussion
Libraries
The numbers of transcriptome PETs (including the dupli-
cates) totaled 91,977 (equivalent to 45,465 unique PETs)
and 68,880 (equivalent to 51,352 unique PETs) for the
r
s
=
+ ()
(
number of PET counts in melanoma
number of PET coun
0
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PET clustering and library comparison Figure 2
PET clustering and library comparison. PETs are clustered first based on their annotated known genes, if available. PETs 
that cannot be annotated to any known gene are clustered based on their chromosome locations (genome coordinates). 
Library comparisons can be conducted at various levels including PET, cluster, gene, and TSS/PAS variant. The PET level com-
parison measures the degree of overlap between unique PETs across two datasets. The cluster level comparison evaluates the 
similarity between two libraries for both known gene clusters and novel clusters, while the gene level comparison considers 
only known gene clusters. The TSS/PAS variant comparison compares alternative TSSs and PASs present in the known gene 
clusters. TSS, transcription start site; PAS, polyadenylation site; chrLoc, chromosome location.
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PET-to-pathway display Figure 3
PET-to-pathway display. The KEGG pathway display (I) was modified to reflect library information. Solid squares were 
added to the upper left corner of the gene box (green icon, with 4 numbers to represent a particular KEGG gene ID). Each 
square is associated with a library and highlighted with red, yellow, or blue color to indicate that gene isoforms are all matched, 
partially matched, or completely unmatched, respectively, by PETs of the library. By placing the cursor on a particular entity 
(mouse on), one can view the description of all gene isoforms in the gene box (II), or PET counts, in cpm (counts per million), 
of a corresponding gene isoform for each library (III & IV). In response to a clicking on a solid square, detailed mapping informa-
tion is displayed (V). Hyperlinks in II lead to all KEGG pathway images that contain the selected gene isoform.
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B16F1 melanoma library and Melan-a2 melanocyte
library, respectively (Table 1). After mapping and further
characterization, we identified 32,267 PET1 ditags from
the melanoma transcriptome. Among these, 29,439
(91.2%) were associated with known genes, and 11,687
(36.2%) of the known gene-associated PET1 ditags were
further annotated to KEGG pathways. The melanocyte
transcriptome contained 36,623 PET1 ditags, 33,005
(90.1%) were associated with known genes, of which
13,348 (36.4%) were further annotated to KEGG path-
ways. Overall, the melanocyte library scored the highest
success rate (40.4%) for known gene-to-pathway associa-
tion, followed by the melanoma library (39.7%), the
E17.5 day old embryo library (37.8%), and the E14 stem
cell library (32.9%). The distinct difference in annotatable
rate between the melanocytic libraries and the embryonic
libraries (especially the E14 stem cell) suggests that certain
developmental pathways are presently uncharacterized
and not available in the KEGG databases.
Melanin de novo biosynthesis genes are highly expressed in 
the cells of melanocyte origin, but not in the embryonic 
cells
The melanogenic potential is genetically endowed by two
groups of genes encoding enzymes of Tyrosinase family
and Pmel/Si family [31], which work in the up- and
down-stream of the melanin biosynthesis pathway respec-
tively. Members of the Tyrosinase family include tyrosi-
nase precursor (encoded by Tyr  gene), Dopachrome
tautomerase precursor (Dct, or Tyrp2  gene), D-
dopachrome tautomerase (Ddt gene), and DHICA oxidase
precursor (Tyrp1 gene). The silver locus protein (Si) is the
murine homolog of human Pmel 17 protein.
As expected, melanin biosynthesis genes were predomi-
nantly expressed in the melanocytic cells including the
B16F1 melanoma cells and the Melan-a2 melanocytes,
but not, or at extremely low levels, in the embryonic cells
including E17.5 embryo cells and E14 embryonic stem
cells (Table 2). Moreover, comparisons between
melanoma cells and melanocytes revealed a pathway-
wide, consistent transcriptional reduction of the major
melanin biosynthesis genes in melanoma (p = 0.0018)
especially for genes expressed at high level in melanocytic
cells, indicating a coordinated transcriptional control for
genes of the same metabolic pathway. This result thus sug-
gests the feasibility of using PET counts for the pathway-
wide quantification of gene expression levels.
The most significantly upregulated pathways are diversely 
involved in various cellular activities
A total of 7 pathways were found to be significantly upreg-
ulated (p < 0.005) in melanoma cells, and these were
Table 1: Library statistics.
Library #Total PETs #uPETs #Mappable
(% over uPETs)
# PET1 #Known gene-asso.
PET1 (% over PET1)
#Pathway-asso. PET1
(% over PET1)
(% over known gene-asso. PET1)
B16F1 melanoma (SMT001) 91977 45465 34146 (75.1%) 32267 29439 (91.2%) 11687
(36.2%) (39.7%)
Melan-a2 melanocyte (SMN001) 68880 51352 38640 (75.3%) 36623 33005 (90.1%) 13348
(36.4%) (40.4%)
E14 Stem Cell (MoEScom) 248234 135328 97295 (71.9%) 93384 86019 (92.1%) 28311
(30.3%) (32.9%)
E17.5 embryo (SME006) 81793 41595 30883 74.3% 28387 24656 (86.9%) 9314
(32.8%) (37.8%)
uPETs, PETs having unique sequences. Mappable ratio is the percentage of unique PETs that have one or more target locations in the genome. PET1 
ratio refers to the percentage of mappable PETs that have unique targets in the genome. Pathway-asso. PET1 is the percentage of PET1 ditags that 
can be assigned to KEGG pathways.
Expression graph of oxidative phosphorylation and ATP syn- thesis pathways Figure 4
Expression graph of oxidative phosphorylation and 
ATP synthesis pathways. PET counts, in cpm (counts per 
million), of gene isoforms in the oxidative phosphorylation 
pathway (red) and the ATP synthesis pathway (blue) are plot-
ted to show that both pathways are downregulated in B16F1 
melanoma cells (library SMT001_32267nr2), compared with 
Melan-a2 melanocytes (SMN001_36623nr2). This function is 
implemented in a local KEGG-PET application for pathway 
analysis. As exemplified by the box in the lower-right corner, 
PET counts of each gene isoform (Cox8a in this case) for all 
libraries are accessible by using mouse-on method.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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either related to purine, amino acid, or lipid biosynthesis,
or the degradation of xenobiotic compounds (Table 3).
High activation of the purine biosynthesis pathway
occurred in most of the enzymes involved in ATP or GTP
synthesis, starting from the biosynthesis of ribose 5-phos-
phate all the way through PRPP, inosinate (IMP), xanthyl-
ate, to the formation of ATP and GTP. The
aminophosphonate metabolic pathway upregulation
might lead to an increase in phospholipid biosynthesis.
Upregulation of nitrobenzene degradation and bisphenol
A degradation pathways would help melanoma cells
detoxify xenobiotic compounds, in which cytochrome
P450 plays an important role. Transcription of P450 per se
was increased from an undetectable level in melanocytes
to 44 cpm in melanoma cells. Biosynthesis of the amino
acid tyrosine was activated in melanoma cells as suggested
by the transcriptional upregulation of tyrosine biosynthe-
sis genes. However, the utilization of tyrosine residues in
melanoma cells is unclear because the transcriptional lev-
els of the enzymes involved in consuming tyrosine for
melanin synthesis in melanoma were all lower than in
melanocytes (4.4, 1.6, and 2.2 fold differences for Tyr,
Tyrp1, and Dct, respectively) and enzymes involved in
downstream tyrosine utilization were mostly lower in
melanoma cells. Lastly, transcriptional activation was
found in most of the enzymes of the galactose pathway,
especially those involved in the galactose-glucose inter-
conversion process (Table 4) including galactosekinase 1,
UDP-galactose-4-epimerase, and UDP-glucose pyrophos-
phorylase 2, suggesting that melanoma cells are more
active than melanocytes in using galactose not only to use
it as the carbon and energy sources, but also for detoxifi-
cation because galactose is highly toxic if accumulated in
the cell.
Glycolysis is the biological process that converts glucose
to pyruvate with ATP production. The process can be
divided into upstream and downstream processes. The
upstream process converts one molecule of glucose into
one molecule of dihydroxyacetone phosphate (which is
subsequently converted into glyceraldehyde 3-P) and one
molecule of glyceraldehyde 3-P. The downstream process
converts two glyceraldehyde 3-P molecules into two pyru-
vate molecules.
In melanoma cells, although the overall glycolysis path-
way is not upregulated, most of the enzymes involved in
the upstream reaction were upregulated, especially phos-
phoglucose isomerase (255:450 in cpm), which intercon-
verts glucose 6-P and fructose 6-P, and aldolase
(1263:1784 in cpm), which interconverts fructose 1,6-
bisphosphate and glyceraldehydes 3-P/dihydroxyacetone
phosphate.
The PI3K/Akt lipid kinase signaling pathway, which is
involved in diverse cellular activities including glucose
metabolism, was activated in melanoma cells. Expression
levels of PI3K and Akt were 11 cpm and 176 cpm, respec-
tively, in melanoma cells; compared with 0 cpm and 90
cpm in melanocytes.
Most of the significantly downregulated pathways reside in 
mitochondria and are related to energy metabolisms 
through the electron transport chain
Eight pathways were found significantly downregulated
(p < 0.005) in melanoma cells (Table 3). Three of them
were excluded by manual curation due to the following
reasons: 1) The Reductive carboxylate cycle is actually a
reverse TCA cycle, and TCA cycle was already included. 2)
The C5-branched dibasic acid metabolism pathway com-
prises only two genes, IlvB and Sucla2; and Sucla2 encodes
a succinate-CoA ligase, which is also a component of the
TCA cycle. 3) Lastly, the pyrimidine biosynthesis pathway
consists of 72 gene isoforms listed in the KEGG database,
of which 12 were shown to be downregulated and another
12 were shown to be upregulated (as defined by r ≤ 0.67,
Table 2: Expression levels of melanin biosynthesis genes.
Library Gene B16F1 melanoma cells Melan-a2 melanocytes E14 Stem Cell E17.5 embryo Descriptions
PET counts (cpm)
Tyr 185 798 0 0 Tyrosinase precursor; Albino locus protein; 
Belong to tyrosinase gene family.
Dct (Tyrp2) 1468 3208 0 0 Dopachrome tautomerase precursor; 
Tyrosinase-related protein 2; Belong to 
tyrosinase gene family.
Ddt 65 58 44 0 D-dopachrome tautomerase.
Tyrp1 1750 2816 0 0 5,6-dihydroxyindole-2-carboxylic acid (DHICA) 
oxidase precursor; Belong to tyrosinase gene 
family.
Si 4751 7985 125 12 Melanocyte protein Pmel 17 precursor (Silver 
locus protein).BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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see Methods section), making it difficult to draw a conclu-
sion. Thus, a total of 5 pathways were characterized as the
most significantly downregulated pathways.
The top 4 of these pathways were oxidative phosphoryla-
tion (biosynthesis of ETC components), ATP synthesis
(biosynthesis of ATPase subunits), TCA cycle, and pyru-
vate metabolism (Figure 4), all of which take place in the
mitochondria and are directly or indirectly involved in
ATP production through ETC. Cytochrome C (a compo-
nent of oxidative phosphorylation) decreased 2.6 folds.
Two of the most striking observations of the pyruvate
pathway were: 1) Universal downregulation of all
enzymes that convert pyruvate to Acetyl-CoA, including a
5-fold decrease for pyruvate dehydrogenase (Pdhb), a 6.8-
fold decrease for dihydrolipoamide dehydrogenase (Dld),
Table 4: Expression levels of galactose-glucose interconversion pathway genes.
PET counts (cpm)
Substrates/Products Products/Substrates Enzyme Gene name Melan-a2
melanocytes
B16F1
melanoma cells
galactose galactose 1-P galactokinase Galk1 01 5 4
galactose 1-P + UDP-glucose UDP-galactose + glucose1-P galactose 1-P uridyl transferase Galt 45 33
UDP-galactose UDP-glucose UDP-galactose-4-epimerase Gale 03 3
glucose 1-P UDP-glucose UDP-glucose pyrophosphorylase2 Ugp2 284 863
Enzymes of galactose-glucose interconversion pathway were extracted from KEGG galactose metabolism pathway.
Table 3: The most significantly altered pathways in melanoma cells.
Pathway ID Description KEGG Category/Description* # genes # up-regulated
genes
# down-regulated
genes
p-value
up-regulated
230 Purine metabolism Nucleotide Metabolism 119 11 23 4.37E-05
440 Aminophosphonate 
metabolism
Metabolism of Other Amino 
Acids
12 0 6 0.000153
626 Nitrobenzene degradation Biodegradation of 
Xenobiotics
11 0 5 0.00098
363 Bisphenol A degradation Biodegradation of 
Xenobiotics
16 0 6 0.00101
350 Tyrosine metabolism Amino Acid Metabolism 44 6 10 0.00196
450 Selenoamino acid 
metabolism
Metabolism of Other Amino 
Acids
20 0 6 0.00370
52 Galactose metabolism Carbohydrate Metabolism 27 2 7 0.00429
4540 Gap junction Cell Communication 85 4 14 0.00670
340 Histidine metabolism Amino Acid Metabolism 31 1 7 0.00964
4110 Cell cycle Growth and Death 98 2 15 0.01009
Down-regulated
190 Oxidative phosphorylation Energy Metabolism 128 46 8 2.95E-27
193 ATP synthesis Energy Metabolism 42 14 4 2.68E-08
720 Reductive carboxylate cycle Energy Metabolism 10 6 0 5.25E-06
20 Citrate cycle (TCA cycle) Carbohydrate Metabolism 26 9 2 6.56E-06
620 Pyruvate metabolism Carbohydrate Metabolism 35 8 5 0.00057
240 Pyrimidine metabolism Nucleotide Metabolism 72 12 12 0.00057
660 C5-branched dibasic acid 
metabolism
Carbohydrate Metabolism 2 2 0 0.00319
480 Glutathione metabolism Metabolism of Other Amino 
Acids/Neutralization of ROS*
37 7 1 0.00400
280 Valine, leucine and isoleucine 
degradation
Amino Acid Metabolism 39 7 6 0.00543
Pathways with p-values around 0.010 or lower are listed. The most significantly altered pathways (p ≤ 0.005) after being validated with manual 
curation are shown in bold.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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and a 2.7-fold decrease for dihydrolipoamide S-acetyl-
transferase (Dlat). 2) A10.5-fold increase of lactate dehy-
drogenase 1, A chain (Ldh1), which interconverts pyruvate
and D-lactate. Thus, melanoma cells tend to consume
pyruvate through anaerobic fermentation. Since Acetyl-
CoA is the intermediate metabolite that enters the TCA
cycle for ATP production through ETC, downregulation of
Acetyl-CoA production well correlates with the downreg-
ulation of TCA cycle, oxidative phosphorylation, and ATP
synthesis pathways.
Glutathione molecules are the major group of non-pro-
tein thiols in the cell. They mainly act as antioxidants (e.g.
Glutathione peroxidases), reducing agents (e.g. Glutath-
ione dehydroascobate reductase), and detoxification
agents (e.g. Glutathione-dependent S-transferase), and
form a redox buffer in the cell through the interconversion
between reduced monomers and oxidized dimers medi-
ated by di-sulfide bond breakage or formation, respec-
tively. Downregulation of glutathione metabolism was
observed mainly in two routes: 1) the interconversion
between the reduced and the oxidized forms of glutath-
ione, and 2) the transition from the reduced glutathione
to R-S-glutathione (Figure 5). In these regions, 87.5% (14/
16) of the gene isoforms showed reduced expressions.
Downregulation of glutathione metabolism might be
related to the downregulation of the above-mentioned
mitochondrial pathways. Reduced TCA cycle and ETC
activities implied lower reactive oxygen species (ROS)
production. Thus, the synthesis of glutathione pathway
enzymes was reduced accordingly. Using proteomic and
SAGE profiling de Souza et al. also observed the same
trend in melanoma cell lines Tm1 and Tm5, when com-
pared with the melan-a melanocyte from which the Tm1
and Tm5 were derived [32].
Upregulation of RAS-MAPK pathway genes, and c-Myc in 
B16F1 melanoma cells
Activation of the mitogen activated protein kinase
(MAPK) pathway occurs in most tumors and is a common
event in uveal melanomas, although it rarely occurs
through mutation of RAS or BRAF [1,33,34]. The RAS-
MAPK cascade activates c-fos, c-Myc and stress-activated
protein kinases (MSKs), which in turn phosphorylate his-
tone H3, leading to chromatin remodeling and activation
of specific genes [35].
We found transcriptional upregulation in melanoma cells
across major RAS-MAPK (ERK1) pathway genes including
Ras, Raf, Mek, and Erk, together with a significant isoform
switch in Ras transcripts (Table 5). Within Ras isoforms,
there was a 4-fold decrease for H-ras1, a 3-fold increase for
R-ras, and a plausible induction of K-ras in melanoma
cells (0 cpm in melanocytes, compared with 11 cpm in
melanoma cells). Recent reports indicate that expression
of the K-ras  oncogene accelerates tumorigenesis in the
context of APC deficiency [36]. In this study, PTEN, APC,
and BRAF (B-type RAF kinase) transcripts were not
detected in both cell types.
The expression level of c-Myc was 33 cpm (with two iso-
forms) in melanoma cells, as compared with an undetec-
table level in melanocytes. c-MYC protein was shown to
play a crucial role in human carcinogenesis, and β-catenin
(the effector protein of the Wnt signaling) was able to acti-
vate c-Myc expression [37] in the presence of TCF/LEF. The
enhanced expression of c-Myc contributes to most aspects
of tumor cell biology, including cell cycle progression, cell
differentiation, apoptosis, metastasis and angiogenesis
[7,38]. Activated c-Myc [5] or Ras [39] can induce chromo-
some breakage and increase the frequency of gene ampli-
fication. Crosstalk between c-MYC and other pathways,
including p53 and Wnt/β-catenin pathways has been
shown to exert profound effects on many cellular aspects.
Upregulation of Trp53, and cell cycle progression gene 
expressions
p53 plays an important role in suppressing tumor devel-
opment and p53 mutations have been found in 50% of
human cancer patients [40]. The mouse p53-encoding
gene Trp53 of B16F1 was previously characterized as a
wild-type by genetic studies [13] and the p53 protein,
although expressed at low level, was localized to the
nucleus and thus expected to be functionally normal.
However, we detected a level of 262 cpm for Trp53 mRNA
in B16F1 melanoma cells, in contrast to an undetectable
level in Melan-a2 melanocytes (Figure 6). The upward
transcriptional regulation of p53 did not seem to be com-
patible with its (low) protein level and might imply a
translational control or protein degradation of p53 in
melanoma cells. Genetic studies also identified a deletion
spanning across the overlapping loci encoding p16INK4a
and p19ARF proteins (mouse Cdkn2a of Ink4a-d, shown on
the left-hand side of Figure 6) [13,41]. The deletion is sup-
posed to derepress the cell cycle arrest by INK4a protein,
which would otherwise binds to CDK4,6 and causes cell
cycle arrest at G1 phase. In line with the report, the
Cdkn2a  (and  Arf) transcript was not detected in
melanoma cells. ARF protein counteracts the degradation
of p53 by MDM2; thus, deletion in the Arf gene would
reduce the protein level of p53. It is likely that the tran-
scription activation of p53 in melanoma cells was due to
activation by c-MYC. The presence of the E-box in the p53
promoter directly places p53 under the transcriptional
control by c-MYC, and it is not surprising to see co-activa-
tion of p53 and c-MYC [42,43]. Elevation of p53 pathway
expression was also shown in cMYC induced DNA dam-
age and RAS activation [44].BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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Downregulation of glutathione metabolism in melanoma cells Figure 5
Downregulation of glutathione metabolism in melanoma cells. The central panel displays a partial KEGG image of the 
glutathione metabolism pathway. In each active 'gene box' (green), two solid squares are added to the upper left corner to 
reflect the associated information for the Melan-a2 melanocyte library (SMN001_36623nr2, left) and the B16F1 melanoma 
library (SMT001_32267nr2, right). PET counts associated with each gene isoform can be accessed by clicking on the library 
squares. Gene isoform-associated PET counts of the melanocyte library and the melanoma library are displayed side by side 
and compared to demonstrate the transcriptional downregulation of these gene isoforms in melanoma cells. PET counts are 
normalized to cpm (counts per million).
1.8.1.7 (Glutathione reductase 1)
1.1.1.42 (Isocitrate dehydrogenase)
1.1.1.49 (Glucose-6-phosphate 
dehydrogenase)
2.5.1.18 (Glutathione S-transferase)
1.11.1.9 (Glutathione 
peroxidase)BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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Besides p53, the tumor suppressor genes Atm and Cdkn1a
(p21 gene) were expressed higher in melanoma cells than
melanocytes (65:0 and 22:0 in cpm, respectively). It was
reported that the expression levels of c-MYC, proliferating
cell nuclear antigen (PCNA), and p53 were all higher in
metastasizing colorectal cancer than non-metastasizing
tumors as detected by immunohistochemistry [6].
Cell cycle progression is tightly regulated by two types of
controls: a rhythmic expression of cyclins in conjunction
with their interactions with their kinase partners, and a
supervisory control through diversified checkpoint moni-
toring mechanisms [45]. PCNA, a nuclear protein used as
an indicator of cell proliferation, increased from 104 cpm
in melanocyte to 1311 cpm in melanoma (12.6 fold),
implying aggressive growth of melanoma cells. In general,
compared to melanocytes, the transcriptional levels of
cyclins and cyclin-dependent kinases are all elevated in
melanoma cells (Figure 6).
Perturbations in apoptosis pathway: elevation of caspase 
8 transcription and E2f1-to-E2f4 switch
Two alterations were apparent in melanoma apoptosis
pathway: elevation of caspase 8 transcription and an E2f1-
to-E2f4 gene isoform switch.
Expression of caspase 8 was significantly increased (0:154
cpm) in melanoma cells. Both Bad and Bax expression lev-
els were increased slightly and Bad showed isoform induc-
tion, suggesting that there might be apoptotic pressures,
causing the pathway to be upregulated at some points.
However, like the p53 pathway, the apoptosis pathway
seemed to be disoriented and deregulated.
We found an E2f1-to-E2f4  switch in melanoma cells,
wherein p73 transcript was not present. E2Fs are known to
be crucial regulators of a variety of cellular events includ-
ing cell cycle progression, DNA replication, checkpoint
control, apoptosis, and DNA repair [46], and E2F1 is cru-
cial for E2F-dependent apoptosis [47,48]. In general, E2Fs
can be divided into activators (E2F1-3) and repressors
(E2F4 and E2F5). However, it is technically possible for
the repressors to activate certain genes. E2F1 induces the
transcription of p73 which in turn activates the apoptosis
pathway [40,49]. The capability of p73 to induce apopto-
sis in TP53-/- cells is a p53-independent tumor control
mechanism that runs in parallel with p53-dependent
apoptosis. There were six E2f gene isoforms (E2f1-E2f6)
listed in KEGG database, among which melanocytes
expressed  E2f1  (60 cpm) and E2f5  (15 cpm), while
melanoma cells expressed E2f4 (11 cpm) and E2f5 (11
cpm). It seems likely that melanoma cells adopt the E2f1-
to-E2f4 switch as a strategy to avoid E2F1-p73-dependent
apoptosis. As E2Fs regulate a broad spectrum of cellular
activities, it remains to be learned how such a switch in
E2f isoforms affects overall cancer cell physiology. It is
possible that melanoma cells may still express E2f1 at a
redefined basal level below our detection limit to sustain
the transcription of certain genes.
Cell adhesion and metastasis related genes were expressed 
as diverse isoforms in melanoma cells
Recently β-catenin has drawn a great attention due to its
dual role in signal transduction and cell adhesion. It is not
only a transcription factor that activates genes such as c-
Myc, but also a structural adaptor protein that bridges
extracellular cadherins through α-catenin to the intracel-
lular actin cytoskeleton network, which is crucial for cell-
cell adhesion and migration [9].
Metastases are responsible for most cancer deaths and the
involvement of adhesion proteins in metastasis has been
well documented [1,8]. Since B16F1 is a metastatic
melanoma cell line, it is of particular interest to find out
what adhesion proteins are expressed in melanoma cells.
In both normal melanocytes and melanoma cells, tran-
Table 5: Transcription levels of RAS-MAPK pathway genes.
PET counts (cpm)
Library PKA PKB (Akt) PKC Ras Raf Mek1 Mek2 Erk
H-ras K-ras M-ras N-ras R-ras
Melan-a2 melanocytes 0 90 15 89 0 30 15 60 58 15 44 73
total: 194
B16F1 melanoma cells 33 176 97 22 11 0 11 186 108 98 130 98
total: 230
Expression levels of the major components of RAS-MAPK pathway are listed along with that of PKA, PKB, and PKC, which are also KEGG MAPK 
pathway components.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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Upregulation of cyclins and CDKs in melanoma cells Figure 6
Upregulation of cyclins and CDKs in melanoma cells. Part of KEGG cell cycle pathway is shown on top with a focus on 
cyclins and CDKs and their associated PET counts. Two solid squares are added to each active 'gene box' (green) for accessing 
PET data related to gene isoforms: the left square links to the Melan-a2 melanocyte library (SMN001_36623nr2), while the 
right square links to the B16F1 melanoma library (SMT001_32267nr2). The degree of PET-to-gene isoform matching is indi-
cated by different colors: blue, no match at all; yellow, partially matched; and red, all isoforms matched (by PETs). Boxes in the 
lower portion show PET counts for the gene isoforms of each pair of cyclin (top) and CDK (bottom). PET counts have been 
normalized to cpm (counts per million).BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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scripts of extracellular adhesion proteins such as nectin
(weak cell-cell glue protein) and cadherin (strong cell-cell
glue protein) were low or not detected (Table 6), suggest-
ing that minimal cell-cell contact through cadherin was a
common scheme for both cell lines. However, it could be
an artifact resulted from the process of cell culture. Like
that of β-catenin, integrin expression was very diverse in
melanoma cells. The two expressed integrin genes
included: full-length (exon 1–16) Itgb1 (expressed in both
cell types, but melanoma cells had one extra isoform with
the PAS located in exon 10); and Itgb5  (specifically
expressed 3 different types of isoforms – with different
TSSs – in melanocytes). An 8-fold increase for CD44 iso-
forms (S1E14T14, accompanied with S1E12T14 and
S1E4T14 that were expressed at lower level) was found in
melanoma cells. Since CD44 is able to induce integrin-
mediated adhesion of colon cancer cell lines to endothe-
lial cells [50], the process by which CD44 interacts with
such diversified integrin isoforms is an interesting issue to
be addressed. Moreover, CD44 was identified as a marker
of cancer progression and its variants play a role in metas-
tasis [51]. There were 4.6× and 5.8× increases for Actb and
Actg1 isoforms of the cytoskeleton protein actin, respec-
tively, in melanoma cells as compared with melanocytes.
The increase in actin expression may not be relevant to
metastasis; it may contribute to the identity of melanoma
skin cancers as solid tumors instead.
TSS/PAS variants
Besides the transcript variants resulted from alternative
splicing, transcriptions using alternative TSSs or PASs gen-
erate different types of transcripts with variations in the
5'UTRs or 3'UTRs, which are more likely to be involved in
regulation of gene expression compared with other (inter-
nal) exons. One of the unique advantages of PET
approach is its capability to precisely map the 5' and 3'
boundaries specified by alternative TSSs and alternative
PASs, respectively. It was reported that a total of 5,401
genes were found to be alternatively spliced in Melan-c
and B16-F10Y melanoma cell lines [25]. Melan-a2
melanocytes and B16F1 melanoma cells are similar to
Melan-c melanocyte and B16-F10Y melanoma cells,
respectively. Among the total of 5,606 genes identified
from melanoma and melanocyte cells, 1,289 genes
(23.0%) exhibited alternative TSSs/PASs, 2,714 genes
(48.4%) showed library-specific expressions, and 1,603
genes (28.6%) expressed only common transcripts (Table
7). In theory, the percentage of genes using alternative
TSSs/PASs is more likely to increase as the library size
increases. Transcriptional control with alternative TSSs or
Table 6: Transcription levels of TSS/PAS variants of cell adhesion-related proteins.
PET counts (cpm) A:B ratio
Protein Gene isoforms Melan-a2 melanocytes (A) B16F1 melanoma cells (B)
Collagen Col2a1 *S6-7E53T53: 15 0 30:0
Col1a2 S31E52T52: 15 0
Integrin Itgb1 S1E16T16: 44 S1E16T16: 11
S1E10T16: 11
44:22
Itgb5 S1E16T16: 15
*S6-7E16T16: 15
S14E16T16: 15
04 5 : 0
Actin Actb S1E2T6: 15
S1E6T6: 399
S4E6T6: 11
S1E2T6: 1896
414:1907
Actg1 S3E6T6: 15
S4E6T6: 15
S1E6T6: 876
S1E6T6: 5260 906:5260
Cadherin Cdh11 (not in KEGG) *S2-3E6-7T13: 15
*S3E6-7T13: 15
*S2-3E6-7T13: 11 30:11
JAM Jam2 S1E10T10: 15 0 15:0
Jam3 S1E9T9: 15 0 15:0
β-catenin Catnb S1E1T15: 30 (skip*)
S1E15T15: 15
S11E15T15: 33 15:33
α-catenin Catna1 S4E18T18: 15 S1E18T18: 22
S1E5T18: 11
S15E18T18: 11
15:44
Snail, Slug Snail, Slug 000 : 0
CD44 Cd44 S1E14T14: 15 S1E14T14: 77
S1E12T14: 33
S1E4T14: 11
l5:121
OPN (osteopontin) Spp1 S1E7T7: 1889 0 1889:0
'S', starting exon; 'E', ending-exon; 'T', total number of exons. *Hyphen (-), matching to intron region.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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PASs seems to be a common mechanism for melanocytic
cells.
Transcription of solute carriers (SLCs)
To gain insight into perturbations in mitochondria, we
analyzed the expression of a group of membrane trans-
porter proteins called solute carriers (SLCs) [52]. A total of
67 SLCs were detected in melanoma and/or melanocyte
transcriptomes. To increase the accuracy of the data, we
excluded the PETs of less than 20 cpm because these were
single count PETs before normalization, resulting in 44
SLCs of reasonable confidence (Table 8). Four discoveries
were made from this dataset: i) SLCs heavily expressed in
melanocytes remained heavily expressed in melanoma,
especially Slc25a5, Slc3a2, and Slc25a3. ii) Among these
highly expressed SLCs, Slc25a5 (an ATP/ADP transporter)
increased by 3.2 folds and was the most noticeable pertur-
bation in SLC expression. iii) SLCs specific to melanoma
cells or melanocytes were expressed at a much lower level,
normally less than 100 cpm, except Slc6a15 (amino acid
and osmolyte transporter) which had a cpm of 109. iv) As
shown by the cell type specific SLCs, melanoma cells
seemed to be more active in the transportation of amino
acids (e.g. Slc6a15, Slc25a13, and Slc7a7), fatty acids (e.g.
Slc27a4), UDP-galactose (e.g. Slc35a2, Slc35a4), Mg++ ion
(e.g. Slc41a3), and citrate/malate (e.g. Slc25a10 [53]). The
melanoma-specific SLC expression levels and Slc25a5
activation level correlated well with the activations of the
purine, galactose, and amino acid related metabolic path-
ways. When these pathways were activated, production of
the proteins involved in the transportation of their sub-
strate and/or products was also increased accordingly.
Conclusion
This study aimed to reveal global pathway aberrations in
melanoma cells using the robust GIS-PET technology in
conjunction with KEGG pathway database and hypergeo-
metric distribution analysis. Surprisingly, all the most sig-
nificantly altered pathways, including 7 upregulated and
5 downregulated pathways, are metabolic pathways. The
most significantly upregulated melanoma pathways are
very diverse as they are involved in a broad spectrum of
cellular activities including purine and amino acid bio-
syntheses, galactose utilization, and detoxification of var-
ious harmful compounds. On the other hand, the most
significantly downregulated pathways are tightly corre-
lated, making the conclusion highly reliable and trustwor-
thy. Here, for the first time in melanoma, we provide
compelling evidence to show that cancer cells tend to
avoid using the most efficient route of ATP production
through electron transport chain, which is located in
mitochondrial inner membrane and which uses oxygen as
the electron receptor.
This notion is mainly based on the observation that mito-
chondria-harbored metabolic pathways are severely
downregulated. In eukaryotic cells, the top 4 of the most
significantly downregulated melanoma pathways consti-
tute an important catabolic flow for intermediate metab-
olite and energy productions (from pyruvate metabolism,
through TCA cycle and oxidative phosphorylation, to ATP
synthesis). To further avoid using this route, melanoma
cells tend to consume pyruvate molecules to produce D-
lactate instead of Acetyl-CoA (a substrate for TCA cycle).
Moreover, in parallel with the metabolic alterations, mito-
chondrial permeability and transportation system are also
redefined. Among the SLCs, we detected upregulation of
citrate/malate exchanger Slc25a10. In exchange for malate
from cytosol, the citrate/malate exchanger exports citrate
from mitochondria into cytosol for lipid biosynthesis
[53]. Since citrate is an intermediate metabolite of TCA
cycle for the generations of NADH and FADH2, which in
turn are passed on to the respiratory chain for ATP pro-
duction, elevation of the citrate/malate exchanger is an
additional step to reduce the capacity for ATP production
through the ETC.
Our data also indicated that melanoma cells increased the
consumption of glucose and galactose for ATP synthesis
and intermediate metabolite production. In melanoma
cells, galactose pathway and the galactose-glucose conver-
sion pathway were both transcriptionally upregulated. We
suspect that these upregulations aimed not only to sup-
port cancer cell proliferation, but also to reduce the intra-
Table 7: Differential gene expression between B16F1 melanoma cells and Melan-a2 melanocytes.
Category 1 (A) 2 (B) 3 (C) 4 (AB) 5 (AC) 6 (BC) 7 (ABC) Total genes Total transcripts
#Gene 1485 1229 1603 258 437 374 220 5606
#Melan-a2 melanocyte-specific tsc (A) 1678 0 0 299 549 0 351 2877
#B16F1 melanoma-specific tsc (B) 0 1409 0 323 0 473 382 2587
#Overlapped tsc (C) 0 0 1681 0 485 423 317 2906
8370
Known genes expressed in Melan-a2 melanocytes and B16F1 melanoma cells are split into 7 categories based on the combination of their transcript 
types. Transcripts can be Melan-a2-specific (A), B16F1-specific (B), or common to both (C); the 7 categories represent all possible combinations. 
For example, each gene in category 1 expresses one or more transcript solely in melanocytes; each gene in category 4 expresses in both cell types 
but has no cross-library overlap in transcript type; and so on. 'tsc', transcript(s).BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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cellular concentration of galactose, which is a potent toxin
for the cell. Running side by side with the upregulated
detoxification pathways, transcriptional upregulation of
the galactose-glucose interconversion pathway would
neutralize the galactose toxicity, which can be critical in
the solid tumor environment where circulation is much
more limited than normal cells. Notice that the expression
of Slc35a2, an UDP-galactose transporter, was also upreg-
ulated by 3.8 folds in melanoma cells. The increased con-
sumption of carbohydrates, intermediate metabolites and
other nutrients from the circulation system for tumor
growth eventually leads to cancer cachexia [54].
Table 8: Transcriptional alterations of solute carriers (SLCs).
SLCs Solute(s) #A-s
tsc
A-s
cpm
#A/B -c
tsc
A-c
cpm
B-c
cpm
#B-s tsc B-s
cpm
(A-s + A-c)
cpm
(B-s + B-c)
cpm
B – A
cpm
Slc25a5 adenine nucleotide (ATP/ADP) 1 15 1 842 2631 3 109 857 2740 1883
Slc3a2 neutral amino acids 2 44 2 1553 1305 5 152 1597 1457 -140
Slc25a3 phosphate 0 0 2 1423 1174 1 43 1423 1217 -206
Slc25a11 2-oxoglutarate/malate 1 15 1 131 120 2 33 146 153 7
Slc20a2 phosphate 1 15 1 189 120 2 22 204 142 -62
Slc2a1 glucose 1 15 1 15 120 0 0 30 120 90
Slc31a1 copper 1 15 1 58 98 0 0 73 98 25
Slc30a9 zinc 1 15 1 29 65 0 0 44 65 21
Slc12a4 K+/Cl- 1 15 1 44 54 0 0 59 54 -5
S l c 3 5 a 2U D P - g a l a c t o s e 11 5 0 0 0 25 4 1 5 5 4 3 9
Slc25a17 adenine nucleotide 1 15 1 116 33 0 0 131 33 -98
Slc25a19 adenine nucleotide 2 29 1 44 33 0 0 73 33 -40
Slc9a3r1 Na+/H+ exchanger 2 29 1 116 11 1 11 145 22 -123
Slc6a9 neurotransmitter, glycine 0 0 1 15 22 0 0 15 22 7
Slc35c2 neutral amino acids 0 0 1 58 11 0 0 58 11 -47
Slc39a6 zinc 1 15 1 15 11 0 0 30 11 -19
Slc6a15 neurotransmitter, aa, osmolytes 0 0 0 0 0 1 109 0 109 109
Slc25a13 aa Q and E 0 0 0 0 0 3 76 0 76 76
Slc2a8 glucose 0 0 0 0 0 1 54 0 54 54
Slco3a1 organic anion 0 0 0 0 0 1 43 0 43 43
Slc35a4 UDP-galactose 0 0 0 0 0 1 33 0 33 33
Slc41a3 mg++ 0 0 0 0 0 1 33 0 33 33
Slc12a5 Na+/Cl- 0 0 0 0 0 1 22 0 22 22
Slc25a10 citrate/malate, dicarboxylate 0 0 0 0 0 1 22 0 22 22
Slc27a4 fatty acids 0 0 0 0 0 1 22 0 22 22
Slc37a3 glycerol-3-P 0 0 0 0 0 1 22 0 22 22
Slc37a4 glycerol-6-P 0 0 0 0 0 1 22 0 22 22
Slc4a2 anion 0 0 0 0 0 1 22 0 22 22
Slc7a7 cation amino acid 0 0 0 0 0 1 22 0 22 22
Slc35a1 CMP-Sialic acid 2 87 0 0 0 0 0 87 0 -87
Slc37a2 glycerol-3-P 4 73 0 0 0 0 0 73 0 -73
Slc15a4 peptide 1 58 0 0 0 0 0 58 0 -58
Slc25a1 citrate 2 58 0 0 0 0 0 58 0 -58
Slc37a1 glycerol-3-P 1 44 0 0 0 0 0 44 0 -44
Slc10a3 Na+/bile acid 2 29 0 0 0 0 0 29 0 -29
Slc22a18 organic cation 1 29 0 0 0 0 0 29 0 -29
Slc33a1 acetyl-CoA 2 29 0 0 0 0 0 29 0 -29
Slc39a1 zinc 1 29 0 0 0 0 0 29 0 -29
Slc39a11 metal ion 1 29 0 0 0 0 0 29 0 -29
Slc39a3 zinc 1 29 0 0 0 0 0 29 0 -29
Slc4a8 anion 1 29 0 0 0 0 0 29 0 -29
Slc6a6 taurine 2 29 0 0 0 0 0 29 0 -29
Slco4a1 anion 1 29 0 0 0 0 0 29 0 -29
'A', Melan-a2 melanocytes; 'B', B16F1 melanoma cells; A/B, for both A and B; '#', number of transcripts; 's', specific; 'c', common; 'tsc', transcript; 
'cpm', PET counts per million; upper panel, common; central panel, melanoma-specific; lower panel, melanocyte-specific; SLCs with PET counts less 
than 20 cpm for both libraries were excluded.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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It is interesting to compare our results with that of Vahsen
et al [55]. AIF (apoptosis inducing factor) is a protein that,
in response to apoptosis induction, translocates from
mitochondria to the nucleus to exert its chromatinolytic
activity. They described that human or mouse cells lacking
AIF would exhibit high lactate production and enhanced
dependency on glycolytic ATP production due to severe
reduction of ETC complex I activity. Moreover, mice with
reduced AIF expression demonstrated a reduced oxidative
phosphorylation. Their results suggested a role of AIF in
the biogenesis and/or maintenance of complex I of the
electron transport chain. In our investigation, AIF tran-
script was not detected in both melanoma and melano-
cyte cells and thus did not contribute to the physiological
differences between melanoma cells and melanocytes.
However, the expression levels of the ETC pathway as well
as the above-mentioned metabolic pathways were all
lower in melanoma cells. Thus, the same phenomena
were observed with different approaches.
Then, how is the slowdown of mitochondrial activities
related to cancer cell survival? Due to the critical role of
mitochondria in apoptosis [56] and the importance of
angiogenesis in cancer neoplasia, we argue that downreg-
ulation of mitochondrial pathways leading to the reduc-
tion of ETC usage by melanoma cells is actually a "one
stone for two birds" strategy, aiming to downgrade the
role of mitochondria in apoptosis and to reduce the
dependency of the cell on angiogenesis for oxygen supply
(and toxic material removal), which is very limited during
the early stage of angiogenesis. Thus, these issues are
tightly correlated and melanoma cells sacrifice the most
efficient way of ATP production in exchange, at least, for a
reduced threat from apoptosis and a reduced dependency
on angiogenesis. This notion further emphasizes the
importance of mitochondria for normal cellular functions
and deregulated mitochondria would favor the survival of
tumor cells. Notice that enhanced detoxification capabil-
ity would also reduce the dependency on angiogenesis for
the removal of toxic compounds.
It is interesting to learn how melanoma cells can still man-
age to grow vigorously (as indicated by the 12.6-fold
increase of PCNA expression level) despite the surveil-
lance of cell cycle progression checkpoints and apoptotic
pathways in the context of such drastic alterations in mul-
tiple pathways. Based on the coexistence of the transcrip-
tional upregulation of Trp53 and Ink4a/Arf deletion in the
p53 pathway, the deregulated cell cycle progression, and
the scattered pattern of alterations in the apoptosis path-
ways, etc., both tumor suppressor mechanism and apop-
tosis pathway seemed to be shattered into discrete pieces
in which the coordination between the components no
longer existed. How these pathways are deregulated and
how changes at the p53 transcription level are translated
to changes in the protein and protein phosphorylation,
which is required for p53 activation, remains to be under-
stood.
Based on the notion that cancers generally develop from
multiple mutations in diverse genes, we would expect
multiple pathways to be altered, as has been shown in our
data. Due to the extensiveness of the renovation of
melanoma pathways, the selectivity for certain anabolic,
catabolic, or signal transduction pathways to be upregu-
lated or downregulated for melanoma cell survival seem
to be taking place through a series of micro-evolution
process involving numerous testing of mutations and
selections in the context of carcinogenesis environment
inside the tumor mass.
Although pathway studies reflect the combinatorial out-
comes of functionally related genes and are supposed to
be more reliable than studies of individual genes or gene
sets, the results, however, were generated only from B16F1
melanoma cell line. The generality need to be confirmed
with other cancer cell lines or cancer tissue samples. By
such additional works, we should also be able to further
clarify how many of these changes were resulted from
adaptation of the cells to in vitro culture conditions.
Moreover, the hypergeometric distribution approach can
be made even more powerful through improving the res-
olution by looking into the sub-pathways for each path-
way. As described in the study of the pyruvate metabolic
pathway, a sub-pathway may be favored against the oth-
ers. Under this situation, the resolution of hypergeometric
distribution would be compromised. To address this
issue, one would have to dissect each pathway into dis-
tinct sub-pathways, which requires laborious functional
studies on each pathway and is a component of our future
work.
In summary, by using the GIS-PET technology in combi-
nation with KEGG database and hypergeometric distribu-
tion analysis, we demonstrate the most significantly
upregulated and downregulated melanoma pathways and
reemphasize the importance of mitochondrial deregula-
tion for cancer survival. Enzymes of the altered pathways,
such as the galactose-glucose interconversion pathway,
signaling pathway components that have been altered,
and the upregulated transporter proteins in melanoma
cells can be tested as drug targets for cancer therapy. We
believe this approach, which can be readily correlated
with other PET approaches such as ChIP-PET, will signifi-
cantly facilitate our understanding of gene expression and
regulation at the pathway level.BMC Cancer 2007, 7:109 http://www.biomedcentral.com/1471-2407/7/109
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